The U.K.’s National Institute for Health and Care Excellence issued a final appraisal determination for Jetrea confirming the vitreomacular traction treatment option will be recommended for reimbursement in England and Wales via the National Health Service, according to a news release.
The final appraisal determination also expanded potential cases in which use of Jetrea (ocriplasmin, ThromboGenics) may be reimbursed to include patients with symptoms of early vitreomacular traction (VMT) such as metamorphopsia, the release said. The treatment is recommended for reimbursement for full-thickness macular hole up to 400 µm in diameter in the absence of epiretinal membrane.
“We feel highly encouraged by the NICE FAD confirming that metamorphopsia is a ‘severe and distressing’ symptom that requires immediate treatment, and that an early treatment with Jetrea should be reimbursed by the NHS,” Patrick De Haes, MD, CEO of ThromboGenics said in the release.
Final reimbursement guidance from NICE is expected later this year, according to the press release.
Alcon, ThromboGenics’ marketing partner, launched Jetrea in the U.K. in April. The treatment gained approval in the European Union from the European Commission in March.